| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $2,722,625 | 8 | 100 |
Sells | $0 | 0 | 0 |
| Invus Global Management, LLC | 1 | $2M | 0 | $0 | $2M | |
| DEBBANE RAYMOND | director | 7 | $722,624 | 0 | $0 | $722,624 |
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing …
Over the last 12 months, insiders at Lexicon Pharmaceuticals, Inc. have bought $2.72M and sold $0 worth of Lexicon Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Lexicon Pharmaceuticals, Inc. have bought $32.04M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Invus Global Management, LLC () — $2M. DEBBANE RAYMOND (director) — $722,624.
The last purchase of 2,000 shares for transaction amount of $2,980 was made by DEBBANE RAYMOND (director) on 2026‑02‑25.
| 2026-02-25 | DEBBANE RAYMOND | director | 2,000 0.0005% | $1.49 | $2,980 | +27.67% | ||
| 2026-02-23 | DEBBANE RAYMOND | director | 100,000 0.0246% | $1.47 | $147,000 | +26.16% | ||
| 2026-02-20 | DEBBANE RAYMOND | director | 100,000 0.0254% | $1.48 | $147,790 | +29.25% | ||
| 2026-02-19 | DEBBANE RAYMOND | director | 50,000 0.0138% | $1.44 | $71,965 | +25.00% | ||
| 2026-02-18 | DEBBANE RAYMOND | director | 133,688 0.0338% | $1.32 | $176,468 | +43.94% | ||
| 2026-02-17 | DEBBANE RAYMOND | director | 76,857 0.0193% | $1.31 | $100,544 | +43.56% | ||
| 2026-02-13 | DEBBANE RAYMOND | director | 57,952 0.0146% | $1.31 | $75,877 | +44.27% | ||
| 2026-02-02 | Invus Global Management, LLC | 1.54M 0.4403% | $1.30 | $2M | +50.40% | |||
| 2023-11-16 | COATS LONNEL | Chief Executive Officer | 90,000 0.0365% | $1.05 | $94,797 | +60.85% | ||
| 2023-11-10 | COATS LONNEL | Chief Executive Officer | 10,000 0.0041% | $1.01 | $10,100 | +69.31% | ||
| 2023-10-12 | DEBBANE RAYMOND | director | 148,820 0.0604% | $1.03 | $153,805 | +61.54% | ||
| 2023-10-11 | DEBBANE RAYMOND | director | 342,874 0.1415% | $1.08 | $370,784 | +57.01% | ||
| 2023-10-10 | DEBBANE RAYMOND | director | 508,306 0.2365% | $1.14 | $579,367 | +50.00% | ||
| 2023-09-14 | WADE JEFFREY L | President and CFO | 10,000 0.0042% | $1.38 | $13,800 | +25.37% | ||
| 2023-08-04 | McDermott Wendy | VP, Human Resources | 6,000 0.0024% | $1.84 | $11,040 | -9.89% | ||
| 2023-06-29 | COATS LONNEL | Chief Executive Officer | 10,000 0.0053% | $2.16 | $21,600 | -21.66% | ||
| 2023-06-26 | COATS LONNEL | Chief Executive Officer | 10,000 0.0053% | $2.18 | $21,792 | -21.43% | ||
| 2023-06-23 | COATS LONNEL | Chief Executive Officer | 10,000 0.0056% | $2.50 | $24,950 | -27.64% | ||
| 2023-06-23 | McDermott Wendy | VP, Human Resources | 10,000 0.0054% | $2.43 | $24,300 | -27.64% | ||
| 2023-06-22 | COATS LONNEL | Chief Executive Officer | 40,000 0.0211% | $2.31 | $92,400 | -25.86% |
| DEBBANE RAYMOND | director | 1906186 0.4284% | $2.78M | 14 | 0 | +18% |
| Invus Global Management, LLC | 1538462 0.3458% | $2.25M | 1 | 0 | ||
| Ulys, LLC | 10 percent owner | 135327888 30.4138% | $197.58M | 4 | 0 | <0.0001% |
| Artal International S.C.A. | 78634381 17.6724% | $114.81M | 4 | 0 | +10.29% | |
| Invus Advisors, L.L.C. | 50859331 11.4302% | $74.25M | 2 | 0 | <0.0001% | |
| Invus Public Equities, L.P. | 32259461 7.25% | $47.1M | 27 | 0 | <0.0001% | |
| Invus C.V. | 30248505 6.7981% | $44.16M | 3 | 0 | +21.63% | |
| COATS LONNEL | Chief Executive Officer | 914359 0.2055% | $1.33M | 12 | 0 | +6.36% |
| WADE JEFFREY L | President and CFO | 264341 0.0594% | $385,937.86 | 3 | 0 | +1.38% |
| SOBECKI CHRISTOPHER J | director | 137293 0.0309% | $200,447.78 | 2 | 0 | <0.0001% |
| Tessmer James F | VP, Finance & Accounting | 71766 0.0161% | $104,778.36 | 1 | 4 | +91.67% |
| BARKER SAM L | director | 52187 0.0117% | $76,193.02 | 4 | 0 | +14.18% |
| McDermott Wendy | VP, Human Resources | 28478 0.0064% | $41,577.88 | 2 | 0 | <0.0001% |
| ROSE CLAYTON STUART | director | 25000 0.0056% | $36,500.00 | 2 | 0 | <0.0001% |
| Mills Barry | director | 25000 0.0056% | $36,500.00 | 1 | 0 | <0.0001% |
| Santini Alexander A | EVP and CCO | 18661 0.0042% | $27,245.06 | 2 | 0 | <0.0001% |
| CASKEY C THOMAS | director | 6300 0.0014% | $9,198.00 | 5 | 0 | +5.92% |
| NIES ALAN S | director | 5000 0.0011% | $7,300.00 | 1 | 0 | <0.0001% |
$10,154,205 | 103 | -4.60% | $631.34M | |
Lexicon Pharmaceuticals, Inc. (LXRX) | $860,541,348 | 82 | -5.10% | $649.64M |
$1,344,238 | 38 | 23.07% | $639.18M | |
$59,156,363 | 22 | 29.25% | $686.5M | |
$22,365,077 | 19 | -27.47% | $674.89M |
| Increased Positions | 51 | +32.9% | 12M | +4.58% |
| Decreased Positions | 60 | -38.71% | 6M | -2.5% |
| New Positions | 23 | New | 4M | New |
| Sold Out Positions | 16 | Sold Out | 926,176 | Sold Out |
| Total Postitions | 146 | -5.81% | 261M | +2.07% |
| Artal Group S.A. | $155,246.00 | 37.52% | 136.18M | 0 | 0% | 2025-09-30 |
| Siren, L.L.C. | $44,368.00 | 10.72% | 38.92M | 0 | 0% | 2025-09-30 |
| Fmr Llc | $44,095.00 | 10.66% | 38.68M | +542,213 | +1.42% | 2025-09-30 |
| Vanguard Group Inc | $10,855.00 | 2.62% | 9.52M | +670,838 | +7.58% | 2025-09-30 |
| Millennium Management Llc | $4,367.00 | 1.06% | 3.83M | +2M | +133.11% | 2025-09-30 |
| Blackrock, Inc. | $3,870.00 | 0.94% | 3.39M | +40,303 | +1.2% | 2025-09-30 |
| Sessa Capital Im, L.P. | $3,420.00 | 0.83% | 3M | 0 | 0% | 2025-09-30 |
| Citadel Advisors Llc | $3,003.00 | 0.73% | 2.63M | +3M | New | 2025-09-30 |
| Cibc Private Wealth Group Llc | $2,736.00 | 0.66% | 2.4M | -50,143 | -2.05% | 2025-09-30 |
| Geode Capital Management, Llc | $2,734.00 | 0.66% | 2.4M | +20,229 | +0.85% | 2025-09-30 |